Span-America Medical Systems, Inc. (SPAN) Stock Competitors & Peer Comparison
See (SPAN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SPAN | $29.99 | +0.00% | 0 | N/A | N/A | N/A |
| SIRO | $109.97 | +0.00% | 22B | N/A | N/A | N/A |
| HIMS | $30.06 | +4.12% | 6B | -298.06 | -$0.09 | N/A |
| NVST | $24.72 | +0.88% | 4B | 61.49 | $0.40 | N/A |
| CON | $28.06 | +3.01% | 3.6B | 20.24 | $1.39 | +0.89% |
| BBNX | $14.36 | -2.25% | 647.5M | -10.61 | -$1.37 | N/A |
| CV | $7.22 | +4.72% | 359.2M | -6.78 | -$1.06 | N/A |
| KDLY | $11.30 | +1.16% | 68.1M | -15.48 | -$0.73 | N/A |
| NEUE | $6.75 | +0.00% | 60.9M | -0.38 | -$17.65 | N/A |
| PARK | $17.66 | -1.64% | 35M | -35.25 | -$0.51 | N/A |
Stock Comparison
SPAN vs SIRO Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, SPAN is priced at $29.99, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas SIRO's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, SPAN is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check SIRO's competition here
SPAN vs HIMS Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, HIMS has a market cap of 6B. Regarding current trading prices, SPAN is priced at $29.99, while HIMS trades at $30.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas HIMS's P/E ratio is -298.06. In terms of profitability, SPAN's ROE is +0.17%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, SPAN is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for SPAN.Check HIMS's competition here
SPAN vs NVST Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, NVST has a market cap of 4B. Regarding current trading prices, SPAN is priced at $29.99, while NVST trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas NVST's P/E ratio is 61.49. In terms of profitability, SPAN's ROE is +0.17%, compared to NVST's ROE of +0.02%. Regarding short-term risk, SPAN is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check NVST's competition here
SPAN vs CON Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, CON has a market cap of 3.6B. Regarding current trading prices, SPAN is priced at $29.99, while CON trades at $28.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas CON's P/E ratio is 20.24. In terms of profitability, SPAN's ROE is +0.17%, compared to CON's ROE of +0.46%. Regarding short-term risk, SPAN is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check CON's competition here
SPAN vs BBNX Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, BBNX has a market cap of 647.5M. Regarding current trading prices, SPAN is priced at $29.99, while BBNX trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas BBNX's P/E ratio is -10.61. In terms of profitability, SPAN's ROE is +0.17%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, SPAN is more volatile compared to BBNX. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check BBNX's competition here
SPAN vs CV Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, CV has a market cap of 359.2M. Regarding current trading prices, SPAN is priced at $29.99, while CV trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas CV's P/E ratio is -6.78. In terms of profitability, SPAN's ROE is +0.17%, compared to CV's ROE of +1.27%. Regarding short-term risk, SPAN is more volatile compared to CV. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check CV's competition here
SPAN vs KDLY Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, SPAN is priced at $29.99, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas KDLY's P/E ratio is -15.48. In terms of profitability, SPAN's ROE is +0.17%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, SPAN is more volatile compared to KDLY. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check KDLY's competition here
SPAN vs NEUE Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, SPAN is priced at $29.99, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas NEUE's P/E ratio is -0.38. In terms of profitability, SPAN's ROE is +0.17%, compared to NEUE's ROE of +0.06%. Regarding short-term risk, SPAN is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check NEUE's competition here
SPAN vs PARK Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, PARK has a market cap of 35M. Regarding current trading prices, SPAN is priced at $29.99, while PARK trades at $17.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas PARK's P/E ratio is -35.25. In terms of profitability, SPAN's ROE is +0.17%, compared to PARK's ROE of -0.24%. Regarding short-term risk, SPAN is more volatile compared to PARK. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check PARK's competition here
SPAN vs PFSA Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, PFSA has a market cap of 120.4K. Regarding current trading prices, SPAN is priced at $29.99, while PFSA trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas PFSA's P/E ratio is -0.02. In terms of profitability, SPAN's ROE is +0.17%, compared to PFSA's ROE of +1.54%. Regarding short-term risk, SPAN is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for SPAN.Check PFSA's competition here
SPAN vs EVHC Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, EVHC has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas EVHC's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, SPAN is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check EVHC's competition here
SPAN vs CYNO Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, CYNO has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas CYNO's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, SPAN is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check CYNO's competition here
SPAN vs COTV Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, COTV has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas COTV's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to COTV's ROE of +0.14%. Regarding short-term risk, SPAN is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check COTV's competition here
SPAN vs AMSG Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, AMSG has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas AMSG's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, SPAN is more volatile compared to AMSG. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check AMSG's competition here
SPAN vs SCAI Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, SCAI has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas SCAI's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, SPAN is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check SCAI's competition here
SPAN vs DSCI Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, DSCI has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas DSCI's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, SPAN is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check DSCI's competition here
SPAN vs PMC Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, PMC has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas PMC's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to PMC's ROE of +0.04%. Regarding short-term risk, SPAN is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check PMC's competition here
SPAN vs SPNC Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, SPNC has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas SPNC's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, SPAN is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check SPNC's competition here
SPAN vs MEDC Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, MEDC has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas MEDC's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to MEDC's ROE of N/A. Regarding short-term risk, SPAN is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for SPAN.Check MEDC's competition here
SPAN vs ABAX Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, ABAX has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas ABAX's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, SPAN is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check ABAX's competition here
SPAN vs ABCO Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, ABCO has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas ABCO's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, SPAN is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check ABCO's competition here
SPAN vs LPNT Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, LPNT has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas LPNT's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, SPAN is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check LPNT's competition here
SPAN vs STJ Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, STJ has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas STJ's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to STJ's ROE of +0.21%. Regarding short-term risk, SPAN is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check STJ's competition here
SPAN vs MZOR Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, MZOR has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas MZOR's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, SPAN is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check MZOR's competition here
SPAN vs EXAC Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, EXAC has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas EXAC's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, SPAN is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check EXAC's competition here
SPAN vs LDR Comparison June 2026
SPAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPAN stands at 0. In comparison, LDR has a market cap of 0. Regarding current trading prices, SPAN is priced at $29.99, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPAN currently has a P/E ratio of N/A, whereas LDR's P/E ratio is N/A. In terms of profitability, SPAN's ROE is +0.17%, compared to LDR's ROE of +1.17%. Regarding short-term risk, SPAN is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for SPAN.Check LDR's competition here